<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220903055865N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-10-02</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the effectiveness of shock wave therapy and mesotherapy</public_title>
      <acronym></acronym>
      <scientific_title>The Comparison of the effectiveness of Piroxicam mesotherapy versus Using Extracorporeal Shock Wave Therapy (ESWT) in Reducing Pain and Improving Function in Patients with rotator caff tendinopathy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-10-07</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65793</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In order to match the patients of the intervention and control groups, the patients are randomly divided.  To perform randomization in this research, permutation block method with 4 samples in each block is used and the randomization list is obtained using Random Allocation software.  We will have two lists of 30 people including intervention and control groups randomly.  In order to hide the random sequence method, another person who is unaware of the research process is presented and the questionnaires are completed by a person who is unaware of the division of groups, Blinding description: Participant: In this study, we do not have the ability to blind the patient, because the patients of both interventions know the type of intervention.  Clinical caregiver: We teach the person who is in charge of the care and follow-up of the patients how to complete the questionnaire. This person has no knowledge of the type of patient intervention.  Researcher: In this study, we do not have the ability to blind the researcher, because the researcher conducts both studies himself and knows the type of intervention received in each group.  Outcome evaluator: Completed questionnaires are given to a person who does not know about the interventions and he is asked to determine the amount of pain reduction and performance increase in each person according to the questionnaire.  Data analyst: Finally, after completing and collecting all the information, the questionnaires are given to a person to check the information, who does not know about any of the work steps and how the intervention is divided.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Shoulder Rotator cuff tendinopathy(Non-specific shoulder pain).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: group A : Treatment of group A is to perform shock therapy session (ESWT) with frequency 10 and impulse 1000, intensity 2 to 3 based on patient tolerance, once a week for 6 weeks at the site of shoulder injury and correct lifestyle and exercise appropriate shoulder pain .Before entering the study and 2, 4, 8, and 12 weeks after the intervention, the patients completed the visual analog scale questionnaires and the Oxford shoulder score. Intervention 2: Control group: group B : subcutaneous injection of 1 ml of piroxicam 20 mg along with 4 ml of lidocaine 2% in the painful points and around the involved shoulder at a distance of at least 1 cm.  Mesotherapy is performed in 3 stages with a one-week interval according to a common and sterile protocol along with the recommendation to follow the correct lifestyle and perform appropriate exercises for shoulder pain.  Before entering the study and 2, 4, 8, and 12 weeks after the intervention, the patients completed the visual analog scale questionnaires and the Oxford shoulder score.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All available data can be shared after de-identifying people

When:
Access starts one year after results are published

To whom:
Everyone will have access to this information.

Conditions:
If the information of this study helps in improving the process of science

Where to obtain:
Fateme nazri/ 00989164900466
W.faezenazari98@yahoo.com

How to obtain:
After sending the desired message, we will talk with all the authors of this study and if necessary, all the information will be sent within a maximum of three weeks.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fateme nazari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 1, No.  50, Peyman Building, Second Branch, 31 Alley, Farhang Shahr, Shiraz, Iran</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7185964655</zip>
        <telephone>36333973</telephone>
        <email>W.faezenazari98@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fateme nazari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 1, No.  50, Peyman Building, Second Branch, 31 Alley, Farhang Shahr, Shiraz, Iran</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7185964655</zip>
        <telephone>36333973</telephone>
        <email>W.faezenazari98@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Completing and signing the consent form
Patients with shoulder pain lasting more than 4 weeks
Shoulder pain with an Oxford shoulder score of at least 4 in the last month
Age over 18
Absence of any type of disease around the relevant joint</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Any pathology found on the plain radiograph, including degenerative findings of the shoulder joint
Any clinical symptoms of effusion, inflammation, redness and warmth of the shoulder
Having diabetes, uncontrolled blood pressure and rheumatic and vascular collagen diseases such as lupus, gout and simultaneous radiculopathy, myopathy, nerve damage and neuropathies such as carpal tunnel syndrome, stroke and any type of systemic infection.
Body mass index above 42
History of joint replacement and trauma and fracture on the side of the involved shoulder
Suffering from bleeding diseases and taking anticoagulant drugs
Psychological problems
Any hypersensitivity to drugs used in the study, such as piroxicam
History of significant heart, kidney, liver, brain, lung disorders
History of injections in or around the affected shoulder joint in the last 3 months
History of shoulder and upper limb physiotherapy in the last one month
Pregnant and lactating woman
Cancer</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M25.519</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pain in unspecified shoulder</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: group A : Treatment of group A is to perform shock therapy session (ESWT) with frequency 10 and impulse 1000, intensity 2 to 3 based on patient tolerance, once a week for 6 weeks at the site of shoulder injury and correct lifestyle and exercise appropriate shoulder pain .Before entering the study and 2, 4, 8, and 12 weeks after the intervention, the patients completed the visual analog scale questionnaires and the Oxford shoulder score.</i_keyword>
      <i_keyword>Control group: group B : subcutaneous injection of 1 ml of piroxicam 20 mg along with 4 ml of lidocaine 2% in the painful points and around the involved shoulder at a distance of at least 1 cm.  Mesotherapy is performed in 3 stages with a one-week interval according to a common and sterile protocol along with the recommendation to follow the correct lifestyle and perform appropriate exercises for shoulder pain.  Before entering the study and 2, 4, 8, and 12 weeks after the intervention, the patients completed the visual analog scale questionnaires and the Oxford shoulder score.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Shoulder pain. Timepoint: Before intervention;  Two weeks, four weeks, eight weeks and twelve weeks later. Method of measurement: Visual analogue scale, Oxford shoulder score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Patient performance. Timepoint: Before intervention;  Two weeks, four weeks, eight weeks and twelve weeks later. Method of measurement: Oxford shoulder scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz university of medical sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-08-21</approval_date>
        <contact_name>Ethics Committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Unit 1, No. 50, Peyman Building, Shahid Rajaee Boulevard, Farhang Shahr, Shiraz, Iran Shiraz Fars Azerbaijan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
